Result of GM & Issue of Equity
ValiRx Plc announced that all resolutions were passed at its General Meeting, leading to the allotment of 256,067,800 new shares, with admission to AIM expected on November 21, 2025. The company also issued 368,372,400 Fundraising Warrants and 16,036,120 Broker Warrants. Following these transactions, the enlarged issued share capital will comprise 742,721,072 ordinary shares. Directors Mark Eccleston, Cathy Tralau-Stewart, Gerry Desler, and Martin Gouldstone participated in the fundraising, acquiring new shares and warrants, which will adjust their respective shareholdings in the enlarged company.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
Director and PDMR Shareholding
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement on 4 November 2025, at the Company's General Meeting held earlier today, all resolutions were duly passed. Details of the votes received in respect of the resolutions will be available shortly on the Company's website.
Issue of Equity
The Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares have been allotted, conditional upon Admission, and application has been made to the London Stock Exchange for, in aggregate, 256,067,800 Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on 21 November 2025, with dealings in the Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares commencing at the same time. The Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares will rank pari passu with all other issued Shares.
Issue of Warrants
Pursuant to the Fundraising and in connection with the issuance of the Fee Shares the Company has issued 368,372,400 Fundraising Warrants. The Fundraising Warrants will be exercisable at a price of 0.5 pence per Ordinary Share and are exercisable at any time until the third anniversary of Tranche 2 Admission.
In addition, the Company has issued 16,036,120 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of Tranche 2 Admission.
Director and PDMR Shareholdings
Following completion of the Fundraising, the shareholdings of the Directors who participated in the Fundraising are set out in the table below:
| Name | Number of existing Ordinary Shares | Percentage of existing issued share capital | Number of New Ordinary Shares | Number of Ordinary Shares on Tranche 2 Admission | Percentage of enlarged share capital on Tranche 2 Admission |
|---|---|---|---|---|---|
| Mark Eccleston | 22,746,187 | 6.08% | 36,000,000 | 58,746,187 | 7.91% |
| Cathy Tralau-Stewart | 835,897 | 0.22% | 1,200,000 | 2,035,897 | 0.27% |
| Gerry Desler | 964,565 | 0.26% | 1,200,000 | 2,164,565 | 0.29% |
| Martin Gouldstone | 769,231 | 0.21% | 1,200,000 | 1,969,231 | 0.27% |
| Total | 25,315,880 | 6.76% | 39,600,000 | 64,915,880 | 8.74% |
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 742,721,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the Circular dated 4 November 2025, unless otherwise defined in this announcement.
The Directors of the Company take responsibility for this announcement.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/yEMZvy |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Broker) Damon Heath Andrew Gutmann | Tel: +44 (0) 20 7186 9000 |
| SP Angel Corporate Finance LLP (Placing Agent) David Hignell Vadim Alexandre | Tel: +44 (0) 20 3470 0470 |
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | A) Mark Eccleston B) Cathy Tralau-Stewart C) Gerry Desler D) Martin Gouldstone |
| 2 | Reason for notification | |
| a. | Position/Status | A) Director B) Director C) Director D) Director |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | ValiRx PLC |
| b. | LEI | 213800VQKB9SJCQDET40 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares ISIN: GB00BLH13C52 |
| b. | Nature of the transaction | Purchase of shares as part of the Fundraising |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| A) 0.25 pence | 36,000,000 | |
| B) 0.25 pence | 1,200,000 | |
| C) 0.25 pence | 1,200,000 | |
| D) 0.25 pence | 1,200,000 | |
| d. | Aggregated information - Aggregated Volume - Price | N/A |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | A) Mark Eccleston B) Cathy Tralau-Stewart C) Gerry Desler D) Martin Gouldstone |
| 2 | Reason for notification | |
| a. | Position/Status | A) Director B) Director C) Director D) Director |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | ValiRx PLC |
| b. | LEI | 213800VQKB9SJCQDET40 |
| a. | Description of the financial instrument, type of instrument Identification Code | Warrants over new Ordinary Shares exercisable at a price of 0.5 pence per share ISIN: GB00BLH13C52 |
| b. | Nature of the transaction | Warrants as part of the Fundraising |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| A) 0.5 pence | 36,000,000 | |
| B) 0.5 pence | 1,200,000 | |
| C) 0.5 pence | 1,200,000 | |
| D) 0.5 pence | 1,200,000 | |
| d. | Aggregated information - Aggregated Volume - Price | N/A |
| f. | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.